CA2054228A1 - Muramyldipeptide derivatives and influenza vaccine comprising the derivatives - Google Patents

Muramyldipeptide derivatives and influenza vaccine comprising the derivatives

Info

Publication number
CA2054228A1
CA2054228A1 CA002054228A CA2054228A CA2054228A1 CA 2054228 A1 CA2054228 A1 CA 2054228A1 CA 002054228 A CA002054228 A CA 002054228A CA 2054228 A CA2054228 A CA 2054228A CA 2054228 A1 CA2054228 A1 CA 2054228A1
Authority
CA
Canada
Prior art keywords
group
carbon atoms
influenza vaccine
vaccine
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002054228A
Other languages
English (en)
French (fr)
Inventor
Masaharu Oki
Hideya Tsuge
Kunio Ohkuma
Tetsuya Oka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Daiichi Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2054228A1 publication Critical patent/CA2054228A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA002054228A 1990-10-30 1991-10-25 Muramyldipeptide derivatives and influenza vaccine comprising the derivatives Abandoned CA2054228A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP29333690 1990-10-30
JP29333590 1990-10-30
JP293335/1990 1990-10-30
JP293336/1990 1990-10-30

Publications (1)

Publication Number Publication Date
CA2054228A1 true CA2054228A1 (en) 1992-05-01

Family

ID=26559366

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002054228A Abandoned CA2054228A1 (en) 1990-10-30 1991-10-25 Muramyldipeptide derivatives and influenza vaccine comprising the derivatives

Country Status (16)

Country Link
US (1) US5292506A (enExample)
EP (2) EP0680974A1 (enExample)
KR (1) KR920008064A (enExample)
CN (1) CN1062146A (enExample)
AU (1) AU642048B2 (enExample)
CA (1) CA2054228A1 (enExample)
FI (1) FI915089A7 (enExample)
HU (1) HUT62199A (enExample)
IE (1) IE913765A1 (enExample)
IL (1) IL99851A (enExample)
MX (1) MX9101820A (enExample)
NO (1) NO914233D0 (enExample)
NZ (1) NZ240369A (enExample)
PT (1) PT99389A (enExample)
RU (1) RU2074192C1 (enExample)
TW (1) TW207545B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612037A (en) * 1994-07-26 1997-03-18 Connaught Laboratories, Inc. Influenza virus subunit conjugates
CN1253220C (zh) * 2001-06-29 2006-04-26 贝克顿迪肯森公司 通过微管在真皮内输入疫苗和基因治疗剂
US20040247661A1 (en) * 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
CN1665487A (zh) * 2002-07-03 2005-09-07 埃弗顿有限公司 脂质体疫苗
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
TWI329130B (en) 2003-06-19 2010-08-21 Bestewil Holding Bv Functionally reconstituted viral membranes containing adjuvant
BRPI0417225A (pt) * 2003-12-05 2007-03-06 Becton Dickinson Co métodos de aumentar a resposta imune no compartimento intradérmico e compostos úteis nos referidos métodos
RS51665B (sr) 2004-09-09 2011-10-31 Novartis Vaccines And Diagnostics Gmbh. Smanjenje potencijalnih jatrogenih rizika povezanih sa vakcinama protiv gripa
AU2005314563B2 (en) 2004-11-03 2011-06-30 Seqirus UK Limited Influenza vaccination
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
CN101100483B (zh) * 2006-07-07 2011-12-07 中国医学科学院药物研究所 胞壁酰二肽的类似物
WO2008024075A1 (en) 2006-08-25 2008-02-28 Agency For Science, Technology And Research Modulators of candida hyphal morphogenesis and uses thereof
WO2008112218A2 (en) 2007-03-12 2008-09-18 Antigen Express, Inc. Li-rnai involved li suppression in cancer immunotherapy
AU2011300402B2 (en) 2010-09-07 2015-01-22 Novartis Ag Generic assays for detection of mammalian reovirus
WO2013172517A1 (ko) 2012-05-16 2013-11-21 서울대학교산학협력단 뮤라밀-다이펩타이드를 포함하는 골소실 예방, 골재생 또는 골형성 촉진용 약학 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6042398A (ja) * 1983-08-18 1985-03-06 Toshiyuki Hamaoka ムラミルジペプチド活性エステル誘導体
JPH0688911B2 (ja) * 1985-06-06 1994-11-09 国立予防衛生研究所長 インフルエンザワクチン及びその製造方法
US4895835A (en) * 1987-11-20 1990-01-23 Nisshin Oil Mills, Ltd. Muramyl peptide derivatives and use thereof
HU205147B (en) * 1989-06-29 1992-03-30 Sandoz Ag Process for producing muramyl dipeptide derivative and pharmaceutical compostions comprising same

Also Published As

Publication number Publication date
MX9101820A (es) 1992-06-05
AU642048B2 (en) 1993-10-07
KR920008064A (ko) 1992-05-27
RU2074192C1 (ru) 1997-02-27
HUT62199A (en) 1993-04-28
IL99851A (en) 1996-06-18
EP0487909A3 (en) 1992-08-12
FI915089A0 (fi) 1991-10-29
HU913398D0 (en) 1992-01-28
US5292506A (en) 1994-03-08
TW207545B (enExample) 1993-06-11
IE913765A1 (en) 1992-05-22
PT99389A (pt) 1992-09-30
FI915089L (fi) 1992-05-01
FI915089A7 (fi) 1992-05-01
NO914233D0 (no) 1991-10-29
NZ240369A (en) 1993-09-27
AU8684991A (en) 1992-05-07
CN1062146A (zh) 1992-06-24
EP0487909A2 (en) 1992-06-03
IL99851A0 (en) 1992-08-18
EP0680974A1 (en) 1995-11-08

Similar Documents

Publication Publication Date Title
US5292506A (en) Muramyldipeptide derivatives and influenza vaccine comprising the derivatives
FI75578B (fi) Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider.
US6113918A (en) Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
HU226869B1 (en) Immunological adjuvant compound and composition containing thereof
WO2007085962A2 (en) Novel glycolipid adjuvant compositions
EP0004512A1 (fr) Composés esters de muramyl-peptide et leurs applications dans les compositions pharmaceutiques et réactifs de laboratoire
US4427659A (en) Muramyl peptide substituted on a peptide nitrogen and medicaments containing the same
JPS6123167B2 (enExample)
US5416070A (en) Composition for macrophage activation
EP0426667A1 (en) COMPOSITION FOR MACROPHAG ACTIVATION.
KR950000780B1 (ko) 만노비오스 유도체
US3840513A (en) Therapeutically useful compound,leupeptins,and processes for the preparation thereof
CN101374551B (zh) 新的糖脂佐剂组合物
EP0013856B1 (en) New compounds associating peptidyl or aminoacyl residues to lipophilic groups and pharmaceutical compositions containing said new compounds
PL123483B1 (en) Process for preparing novel compunds of n-acetylmuramylpeptides type
US4377570A (en) Immunologically active dipeptidyl saccharides and methods of preparation
JPH05229960A (ja) 新規インフルエンザワクチン
JPH0761276B2 (ja) 酵素法リン脂質−ｄ−セリン誘導体の製造法
Agosin Biochemistry and physiology of Echinococcus
JPS60115579A (ja) 酵素阻害剤としてのオクタヒドロインドリジンプロピオン酸類およびその関連化合物
JPS632922A (ja) ドラツグキヤリア
JPS61275299A (ja) デオキシムラミルジペプチド誘導体
JPH05230098A (ja) 新規ムラミルジペプチド誘導体
SU1735307A1 (ru) Конъюгат аденилил(2 @ -5 @ ) аденилил-(2 @ -5 @ ) аденозина с бычьим сывороточным альбумином, используемый дл получени антител, специфичных к 2 @ , 5 @ - олигоаденилатам
Lüderitz et al. Lipid A: relationships of chemical structure and biological activity

Legal Events

Date Code Title Description
FZDE Discontinued